Investigational New Drugs

, Volume 25, Issue 4, pp 305–312 | Cite as

Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines

  • Denise K. Walters
  • Roman Muff
  • Bettina Langsam
  • Philipp Gruber
  • Walter Born
  • Bruno Fuchs
PRECLINICAL STUDIES

Summary

Taurolidine, the active agent of Taurolin®, is a broad spectrum anti-biotic that has been used for over 15 years for the treatment of severe surgical infections. Recently, taurolidine has been shown to possess anti-neoplastic properties in vitro and in vivo against a variety of cancers including ovarian, colon and prostate. In this study we assessed the cytotoxic activity of taurolidine against human osteosarcoma (OS) cell lines and normal human bone cells. Treatment with taurolidine inhibited the growth of all ten osteosarcoma cell lines tested and taurolidine was equally potent against cell lines with and without distinct genetic defects (i.e. p53, Rb). Moreover, taurolidine-induced growth inhibition was found to be associated with a dose dependent increase in the number of apoptotic cells and apoptosis was shown to be caspase-dependent. Taurolidine treatment was also found to inhibit adhesion of OS cell lines. Compared to OS cell lines, normal bone cells in primary culture were found to be less sensitive to the cytotoxic and anti-adhesive effects of taurolidine. These data indicate that taurolidine possesses potent anti-neoplastic activity against osteosarcoma cell lines and may have potential as a novel OS chemotherapeutic agent.

Keywords

Osteosarcoma Taurolidine Chemotherapy 

References

  1. 1.
    Friedman MA, Cater S (1972) The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 4:482–510PubMedCrossRefGoogle Scholar
  2. 2.
    Marina N, Gebhardt M, Teot L, Gorlick R (2004) Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422–441PubMedCrossRefGoogle Scholar
  3. 3.
    Browne MK, MacKenzie M, Doyle PJ (1978) Controlled trial of taurolidine in established bacterial peritonitis. Surg Gynecol Obstet 146:721–724PubMedGoogle Scholar
  4. 4.
    Billing A, Frohlick D, Ruckdeschel G (1992) Der Einfluss von Taurolidine aud die korpereigene Abwehr und die Keimelimination bei der menschlichen Peritonitis. Langenbecks Arch Chir 377:180–185PubMedGoogle Scholar
  5. 5.
    Bohm B, Schwenk W, Muller JM (1998) Long-term results after laparoscopic resection of colorectal carcinoma. Chirurg 70:453–455Google Scholar
  6. 6.
    Knight BI, Skellern GG, Browne MK, Pfirrmann RW (1981) Peritoneal absorption of the antibacterial and antiendotoxin taurolidine in peritonitis. Br J Clin Pharmacol 12:695–699PubMedGoogle Scholar
  7. 7.
    Gidley MJ, Sanders JK, Myers ER, Allwood MC (1981) The mode of antibacterial action of some “masked” formaldehyde compounds. FEBS Lett 127:225–227PubMedCrossRefGoogle Scholar
  8. 8.
    Gorman SP, McCafferty DF, Woolfson AD, Jones DS (1987) Electron and light microscope observations of bacterial cell surface effects due to taurolidine treatment. Lett Appl Microbiol 4:103–109Google Scholar
  9. 9.
    Gorman SP, McCafferty DF, Woolfson AD, Jones DS (1987) Reduced adherence of micro-organisms to human epithelial cells following treatment with Taurolidine, a novel antimicrobial agent. J Appl Bacteriol 62:315–320PubMedGoogle Scholar
  10. 10.
    Calabresi P, Goulette FA, Darnowski JW (2001) Taurolidine: cytotoxic and mechanistic evaluation of a novel anti-neoplastic agent. Cancer Res 61:6816–6821PubMedGoogle Scholar
  11. 11.
    McCourt M, Wang JH, Sookhai S, Redmond HP (2000) Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 7:685–691PubMedCrossRefGoogle Scholar
  12. 12.
    Rodak R, Kubota H, Ishihara H, Eugster HP, Konu D, Mohler H, Yonekawa Y, Frei K (2005) Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vacular endothelial growth factor production by taurolidine. J Neurosurg 102:1055–1068PubMedCrossRefGoogle Scholar
  13. 13.
    Shrayer DP, Lukoff H, King T, Calabresi P (2003) The effect of Taurolidine on adherent and floating subpopulations of melanoma cells. Anti-cancer Drugs 14:295–303PubMedCrossRefGoogle Scholar
  14. 14.
    Nici L, Monfils B, Calabresi P (2004) The effects of Taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 10:7655–7661PubMedCrossRefGoogle Scholar
  15. 15.
    Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W, Brock M (2004) Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 24:1143–1147PubMedGoogle Scholar
  16. 16.
    Hellwinkel OJ, Muller J, Pollmann A, Kabisch H (2005) Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes. J Gene Med 7:407–419PubMedCrossRefGoogle Scholar
  17. 17.
    Boersma HH, Kietselaer B, Stolk L, Bennaghmouch A, Hofstra L, Narula J, Heidendal G, Reutelingsperger C (2005) Past, present, and future of Annexin A5: from protein discovery to clinical applications. J Nucl Med 46:2035–2050PubMedGoogle Scholar
  18. 18.
    Nestler G, Schulz U, Schubert D, Krüger S, Lippert H, Pross M (2005) Impact of taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in rats. Surg Endosc 19:280–284PubMedCrossRefGoogle Scholar
  19. 19.
    Conlan AA, Abramor E, Delikaris P, Hurwitz SS (1983) Taurolidine instillation as therapy for empyema thoracis. A prospective study of 50 patients. S Afr Med J 64:653–655PubMedGoogle Scholar
  20. 20.
    Browne MK (1981) The treatment of peritonitis by an antiseptic—taurolin. Pharmatherapeutica 2:517–522PubMedGoogle Scholar
  21. 21.
    Buhler HU, Mikic S, Wicki O (1978) A new surgical lavage. Helv Chir Acta 45:143–145PubMedGoogle Scholar
  22. 22.
    Jacobi CA, Menenakos C, Braumann C (2005) Taurolidine—a new drug with anti-tumor and anti-angiogenic effects. Anti-cancer Drugs 16:917–921PubMedCrossRefGoogle Scholar
  23. 23.
    Darnowski J, Goulette FA, Cousens LP, Chatterjee D, Calabresi P (2004) Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol 54:249–258PubMedCrossRefGoogle Scholar
  24. 24.
    Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572PubMedCrossRefGoogle Scholar
  25. 25.
    Link MP, Eilber F (1989) Pediatric oncology: osteosarcoma. In: Pizzo PS, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincott, Philadelphia, pp 689–711Google Scholar
  26. 26.
    Meyers PA, Gorlick R (1997) Osteosarcoma. Pediatr Clin N Am 44:973–989CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Denise K. Walters
    • 1
  • Roman Muff
    • 1
  • Bettina Langsam
    • 1
  • Philipp Gruber
    • 1
  • Walter Born
    • 1
  • Bruno Fuchs
    • 1
  1. 1.Laboratory for Orthopaedic Research, Department of Orthopaedics, Balgrist University HospitalUniversity of ZurichZürichSwitzerland

Personalised recommendations